Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice
J. Clin. Invest. Juliana Hamzah, et al. 118:1691 doi:10.1172/JCI33201 [Go to this article.]

Figure 6
T cell accumulation in tumors is promoted by intratumoral anti-CD40/IL-2 treatment. (A) Immunohistochemical analysis depicting RIP1-Tag5 tumor-infiltrating CD8⁺ T cells 7 days after adoptive transfer. Prior to adoptive transfer mice were treated for 3 weeks with IL-2–RGR, anti-CD40–RGR, or a combination of anti-CD40–RGR/IL-2–RGR as shown in Figure 2A. Original magnification, ×10. Scale bars: 100 μm. Quantification of CD8⁺ lymphocytic infiltration after various treatment regimens (n = 8; 5 microscopic fields per tumor). T, adoptive transfer. *P = 0.005, **P < 0.0001 compared with adoptive transfer only. (B) The percentage of transferred anti-Tag CD8⁺ T cells in pancreatic lymph nodes (panc LN) or RIP1-Tag5 tumors over time was tracked by FACS analysis after 1 adoptive transfer (T) in untreated mice, after IL-2–RGR, anti-CD40–RGR, or anti-CD40–RGR/IL-2–RGR treatment (3-week pretreatment before adoptive transfer) (n = 3).